aluates Reports

$ 0.0

Automative

Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Research Report 2026

Published Date: 2026-02-06

Report Code: QYRE-Auto-11G18535

Global Enzymatic Synthesis of Active Pharmaceutical Ingredients APIs Market Research Report 2024

BUY CHAPTERS

Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Research Report 2026

Code: QYRE-Auto-11G18535

Report

2026-02-06

Pages:114

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Suzhou Shengda Pharmaceuticals

Dongya Pharmaceuticals

DSM Sinochem

Harbin Pharmaceutical Group

Shijiazhuang Pharmaceuticals

Fukang Pharmaceuticals

Job-Health

United Pharmaceuticals

Sandoz Inc

Aurobindo Pharma

Strides Pharma

North China Pharmaceutical Group

Novozymes

Evonik

TEVA

Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market

The global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.

Enzymatic synthesis of active pharmaceutical ingredients (APIs) refers to the process of using enzymes as catalysts to convert substrates into APIs under biocatalytic reaction conditions. This method involves selectively catalyzing specific chemical reactions to efficiently and environmentally friendly produce complex drug molecules. Enzymatic synthesis offers advantages such as high selectivity, mild operating conditions, and minimal by-products, and is widely used in the pharmaceutical industry, especially for synthesizing high-value and structurally complex APIs.

The North American market for Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The Asia-Pacific market for Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The global market for Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) in For Oral is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.

Major global companies of Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) include Suzhou Shengda Pharmaceuticals, Dongya Pharmaceuticals, DSM Sinochem, Harbin Pharmaceutical Group, Shijiazhuang Pharmaceuticals, Fukang Pharmaceuticals, Job-Health, United Pharmaceuticals, Sandoz, Aurobindo Pharma, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.

This report delivers a comprehensive overview of the global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs). The Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Report

Report Metric	Details
Report Name	Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market
Segment by Type	Penicillins and Cephalosporins Statins Anti-AIDS Drugs Other
Segment by Application	For Oral For Injection
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Suzhou Shengda Pharmaceuticals, Dongya Pharmaceuticals, DSM Sinochem, Harbin Pharmaceutical Group, Shijiazhuang Pharmaceuticals, Fukang Pharmaceuticals, Job-Health, United Pharmaceuticals, Sandoz, Aurobindo Pharma, Strides Pharma, North China Pharmaceutical Group, Novozymes, Evonik, Teva
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market report?

Ans: The main players in the Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market are Suzhou Shengda Pharmaceuticals, Dongya Pharmaceuticals, DSM Sinochem, Harbin Pharmaceutical Group, Shijiazhuang Pharmaceuticals, Fukang Pharmaceuticals, Job-Health, United Pharmaceuticals, Sandoz, Aurobindo Pharma, Strides Pharma, North China Pharmaceutical Group, Novozymes, Evonik, Teva

What are the Application segmentation covered in the Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market report?

Ans: The Applications covered in the Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market report are For Oral, For Injection

What are the Type segmentation covered in the Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market report?

Ans: The Types covered in the Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market report are Penicillins and Cephalosporins, Statins, Anti-AIDS Drugs, Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Penicillins and Cephalosporins

1.2.3 Statins

1.2.4 Anti-AIDS Drugs

1.2.5 Other

1.3 Market by Application

1.3.1 Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 For Oral

1.3.3 For Injection

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Perspective (2021–2032)

2.2 Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Growth Trends by Region

2.2.1 Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Historic Market Size by Region (2021–2026)

2.2.3 Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Forecasted Market Size by Region (2027–2032)

2.3 Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Dynamics

2.3.1 Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Industry Trends

2.3.2 Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Drivers

2.3.3 Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Challenges

2.3.4 Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Players by Revenue

3.1.1 Global Top Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Players by Revenue (2021–2026)

3.1.2 Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Players (2021–2026)

3.2 Global Top Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Revenue

3.4 Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Concentration Ratio

3.4.1 Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Revenue in 2025

3.5 Global Key Players of Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Head Offices and Areas Served

3.6 Global Key Players of Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs), Products and Applications

3.7 Global Key Players of Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs), Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Breakdown Data by Type

4.1 Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Historic Market Size by Type (2021–2026)

4.2 Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Forecasted Market Size by Type (2027–2032)

5 Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Breakdown Data by Application

5.1 Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Historic Market Size by Application (2021–2026)

5.2 Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size (2021–2032)

6.2 North America Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Country (2021–2026)

6.4 North America Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size (2021–2032)

7.2 Europe Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Country (2021–2026)

7.4 Europe Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size (2021–2032)

8.2 Asia-Pacific Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Region (2021–2026)

8.4 Asia-Pacific Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size (2021–2032)

9.2 Latin America Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Country (2021–2026)

9.4 Latin America Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size (2021–2032)

10.2 Middle East & Africa Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Country (2021–2026)

10.4 Middle East & Africa Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Suzhou Shengda Pharmaceuticals

11.1.1 Suzhou Shengda Pharmaceuticals Company Details

11.1.2 Suzhou Shengda Pharmaceuticals Business Overview

11.1.3 Suzhou Shengda Pharmaceuticals Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Introduction

11.1.4 Suzhou Shengda Pharmaceuticals Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

11.1.5 Suzhou Shengda Pharmaceuticals Recent Development

11.2 Dongya Pharmaceuticals

11.2.1 Dongya Pharmaceuticals Company Details

11.2.2 Dongya Pharmaceuticals Business Overview

11.2.3 Dongya Pharmaceuticals Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Introduction

11.2.4 Dongya Pharmaceuticals Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

11.2.5 Dongya Pharmaceuticals Recent Development

11.3 DSM Sinochem

11.3.1 DSM Sinochem Company Details

11.3.2 DSM Sinochem Business Overview

11.3.3 DSM Sinochem Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Introduction

11.3.4 DSM Sinochem Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

11.3.5 DSM Sinochem Recent Development

11.4 Harbin Pharmaceutical Group

11.4.1 Harbin Pharmaceutical Group Company Details

11.4.2 Harbin Pharmaceutical Group Business Overview

11.4.3 Harbin Pharmaceutical Group Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Introduction

11.4.4 Harbin Pharmaceutical Group Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

11.4.5 Harbin Pharmaceutical Group Recent Development

11.5 Shijiazhuang Pharmaceuticals

11.5.1 Shijiazhuang Pharmaceuticals Company Details

11.5.2 Shijiazhuang Pharmaceuticals Business Overview

11.5.3 Shijiazhuang Pharmaceuticals Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Introduction

11.5.4 Shijiazhuang Pharmaceuticals Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

11.5.5 Shijiazhuang Pharmaceuticals Recent Development

11.6 Fukang Pharmaceuticals

11.6.1 Fukang Pharmaceuticals Company Details

11.6.2 Fukang Pharmaceuticals Business Overview

11.6.3 Fukang Pharmaceuticals Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Introduction

11.6.4 Fukang Pharmaceuticals Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

11.6.5 Fukang Pharmaceuticals Recent Development

11.7 Job-Health

11.7.1 Job-Health Company Details

11.7.2 Job-Health Business Overview

11.7.3 Job-Health Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Introduction

11.7.4 Job-Health Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

11.7.5 Job-Health Recent Development

11.8 United Pharmaceuticals

11.8.1 United Pharmaceuticals Company Details

11.8.2 United Pharmaceuticals Business Overview

11.8.3 United Pharmaceuticals Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Introduction

11.8.4 United Pharmaceuticals Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

11.8.5 United Pharmaceuticals Recent Development

11.9 Sandoz

11.9.1 Sandoz Company Details

11.9.2 Sandoz Business Overview

11.9.3 Sandoz Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Introduction

11.9.4 Sandoz Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

11.9.5 Sandoz Recent Development

11.10 Aurobindo Pharma

11.10.1 Aurobindo Pharma Company Details

11.10.2 Aurobindo Pharma Business Overview

11.10.3 Aurobindo Pharma Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Introduction

11.10.4 Aurobindo Pharma Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

11.10.5 Aurobindo Pharma Recent Development

11.11 Strides Pharma

11.11.1 Strides Pharma Company Details

11.11.2 Strides Pharma Business Overview

11.11.3 Strides Pharma Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Introduction

11.11.4 Strides Pharma Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

11.11.5 Strides Pharma Recent Development

11.12 North China Pharmaceutical Group

11.12.1 North China Pharmaceutical Group Company Details

11.12.2 North China Pharmaceutical Group Business Overview

11.12.3 North China Pharmaceutical Group Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Introduction

11.12.4 North China Pharmaceutical Group Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

11.12.5 North China Pharmaceutical Group Recent Development

11.13 Novozymes

11.13.1 Novozymes Company Details

11.13.2 Novozymes Business Overview

11.13.3 Novozymes Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Introduction

11.13.4 Novozymes Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

11.13.5 Novozymes Recent Development

11.14 Evonik

11.14.1 Evonik Company Details

11.14.2 Evonik Business Overview

11.14.3 Evonik Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Introduction

11.14.4 Evonik Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

11.14.5 Evonik Recent Development

11.15 Teva

11.15.1 Teva Company Details

11.15.2 Teva Business Overview

11.15.3 Teva Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Introduction

11.15.4 Teva Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

11.15.5 Teva Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Suzhou Shengda Pharmaceuticals

Dongya Pharmaceuticals

DSM Sinochem

Harbin Pharmaceutical Group

Shijiazhuang Pharmaceuticals

Fukang Pharmaceuticals

Job-Health

United Pharmaceuticals

Sandoz Inc

Aurobindo Pharma

Strides Pharma

North China Pharmaceutical Group

Novozymes

Evonik

TEVA

List of Tables

Table 1. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Penicillins and Cephalosporins

Table 3. Key Players of Statins

Table 4. Key Players of Anti-AIDS Drugs

Table 5. Key Players of Other

Table 6. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 7. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 8. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Region (US$ Million), 2021–2026

Table 9. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Share by Region (2021–2026)

Table 10. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Forecasted Market Size by Region (US$ Million), 2027–2032

Table 11. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Share by Region (2027–2032)

Table 12. Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Trends

Table 13. Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Drivers

Table 14. Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Challenges

Table 15. Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Restraints

Table 16. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Revenue by Players (US$ Million), 2021–2026

Table 17. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Share by Players (2021–2026)

Table 18. Global Top Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Players by Tier (Tier 1, Tier 2, and Tier 3), based on Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Revenue, 2025

Table 19. Ranking of Global Top Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Companies by Revenue (US$ Million) in 2025

Table 20. Global 5 Largest Players Market Share by Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Revenue (CR5 and HHI), 2021–2026

Table 21. Global Key Players of Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs), Headquarters and Area Served

Table 22. Global Key Players of Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs), Products and Applications

Table 23. Global Key Players of Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs), Date of General Availability (GA)

Table 24. Mergers and Acquisitions, Expansion Plans

Table 25. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Type (US$ Million), 2021–2026

Table 26. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Type (2021–2026)

Table 27. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Forecasted Market Size by Type (US$ Million), 2027–2032

Table 28. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Type (2027–2032)

Table 29. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Application (US$ Million), 2021–2026

Table 30. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Application (2021–2026)

Table 31. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Forecasted Market Size by Application (US$ Million), 2027–2032

Table 32. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Application (2027–2032)

Table 33. North America Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 34. North America Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Country (US$ Million), 2021–2026

Table 35. North America Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Country (US$ Million), 2027–2032

Table 36. Europe Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 37. Europe Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Country (US$ Million), 2021–2026

Table 38. Europe Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Country (US$ Million), 2027–2032

Table 39. Asia-Pacific Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 40. Asia-Pacific Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Region (US$ Million), 2021–2026

Table 41. Asia-Pacific Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Region (US$ Million), 2027–2032

Table 42. Latin America Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 43. Latin America Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Country (US$ Million), 2021–2026

Table 44. Latin America Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Country (US$ Million), 2027–2032

Table 45. Middle East & Africa Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 46. Middle East & Africa Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Country (US$ Million), 2021–2026

Table 47. Middle East & Africa Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Country (US$ Million), 2027–2032

Table 48. Suzhou Shengda Pharmaceuticals Company Details

Table 49. Suzhou Shengda Pharmaceuticals Business Overview

Table 50. Suzhou Shengda Pharmaceuticals Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Product

Table 51. Suzhou Shengda Pharmaceuticals Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (US$ Million), 2021–2026

Table 52. Suzhou Shengda Pharmaceuticals Recent Development

Table 53. Dongya Pharmaceuticals Company Details

Table 54. Dongya Pharmaceuticals Business Overview

Table 55. Dongya Pharmaceuticals Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Product

Table 56. Dongya Pharmaceuticals Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (US$ Million), 2021–2026

Table 57. Dongya Pharmaceuticals Recent Development

Table 58. DSM Sinochem Company Details

Table 59. DSM Sinochem Business Overview

Table 60. DSM Sinochem Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Product

Table 61. DSM Sinochem Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (US$ Million), 2021–2026

Table 62. DSM Sinochem Recent Development

Table 63. Harbin Pharmaceutical Group Company Details

Table 64. Harbin Pharmaceutical Group Business Overview

Table 65. Harbin Pharmaceutical Group Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Product

Table 66. Harbin Pharmaceutical Group Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (US$ Million), 2021–2026

Table 67. Harbin Pharmaceutical Group Recent Development

Table 68. Shijiazhuang Pharmaceuticals Company Details

Table 69. Shijiazhuang Pharmaceuticals Business Overview

Table 70. Shijiazhuang Pharmaceuticals Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Product

Table 71. Shijiazhuang Pharmaceuticals Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (US$ Million), 2021–2026

Table 72. Shijiazhuang Pharmaceuticals Recent Development

Table 73. Fukang Pharmaceuticals Company Details

Table 74. Fukang Pharmaceuticals Business Overview

Table 75. Fukang Pharmaceuticals Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Product

Table 76. Fukang Pharmaceuticals Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (US$ Million), 2021–2026

Table 77. Fukang Pharmaceuticals Recent Development

Table 78. Job-Health Company Details

Table 79. Job-Health Business Overview

Table 80. Job-Health Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Product

Table 81. Job-Health Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (US$ Million), 2021–2026

Table 82. Job-Health Recent Development

Table 83. United Pharmaceuticals Company Details

Table 84. United Pharmaceuticals Business Overview

Table 85. United Pharmaceuticals Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Product

Table 86. United Pharmaceuticals Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (US$ Million), 2021–2026

Table 87. United Pharmaceuticals Recent Development

Table 88. Sandoz Company Details

Table 89. Sandoz Business Overview

Table 90. Sandoz Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Product

Table 91. Sandoz Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (US$ Million), 2021–2026

Table 92. Sandoz Recent Development

Table 93. Aurobindo Pharma Company Details

Table 94. Aurobindo Pharma Business Overview

Table 95. Aurobindo Pharma Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Product

Table 96. Aurobindo Pharma Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (US$ Million), 2021–2026

Table 97. Aurobindo Pharma Recent Development

Table 98. Strides Pharma Company Details

Table 99. Strides Pharma Business Overview

Table 100. Strides Pharma Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Product

Table 101. Strides Pharma Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (US$ Million), 2021–2026

Table 102. Strides Pharma Recent Development

Table 103. North China Pharmaceutical Group Company Details

Table 104. North China Pharmaceutical Group Business Overview

Table 105. North China Pharmaceutical Group Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Product

Table 106. North China Pharmaceutical Group Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (US$ Million), 2021–2026

Table 107. North China Pharmaceutical Group Recent Development

Table 108. Novozymes Company Details

Table 109. Novozymes Business Overview

Table 110. Novozymes Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Product

Table 111. Novozymes Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (US$ Million), 2021–2026

Table 112. Novozymes Recent Development

Table 113. Evonik Company Details

Table 114. Evonik Business Overview

Table 115. Evonik Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Product

Table 116. Evonik Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (US$ Million), 2021–2026

Table 117. Evonik Recent Development

Table 118. Teva Company Details

Table 119. Teva Business Overview

Table 120. Teva Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Product

Table 121. Teva Revenue in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (US$ Million), 2021–2026

Table 122. Teva Recent Development

Table 123. Research Programs/Design for This Report

Table 124. Key Data Information from Secondary Sources

Table 125. Key Data Information from Primary Sources

Table 126. Authors List of This Report

List of Figures

Figure 1. Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Picture

Figure 2. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Share by Type: 2025 vs 2032

Figure 4. Penicillins and Cephalosporins Features

Figure 5. Statins Features

Figure 6. Anti-AIDS Drugs Features

Figure 7. Other Features

Figure 8. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size by Application (US$ Million), 2021–2032

Figure 9. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Share by Application: 2025 vs 2032

Figure 10. For Oral Case Studies

Figure 11. For Injection Case Studies

Figure 12. Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Report Years Considered

Figure 13. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 14. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 15. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Share by Region: 2025 vs 2032

Figure 16. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Share by Players in 2025

Figure 17. Global Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 18. The Top 10 and 5 Players Market Share by Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Revenue in 2025

Figure 19. North America Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size YoY Growth (US$ Million), 2021–2032

Figure 20. North America Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Share by Country (2021–2032)

Figure 21. United States Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size YoY Growth (US$ Million), 2021–2032

Figure 22. Canada Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size YoY Growth (US$ Million), 2021–2032

Figure 23. Europe Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size YoY Growth (US$ Million), 2021–2032

Figure 24. Europe Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Share by Country (2021–2032)

Figure 25. Germany Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size YoY Growth (US$ Million), 2021–2032

Figure 26. France Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. U.K. Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size YoY Growth (US$ Million), 2021–2032

Figure 28. Italy Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. Russia Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. Ireland Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Asia-Pacific Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. Asia-Pacific Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Share by Region (2021–2032)

Figure 33. China Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. Japan Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. South Korea Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. Southeast Asia Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. India Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. Australia & New Zealand Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Latin America Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Latin America Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Share by Country (2021–2032)

Figure 41. Mexico Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Brazil Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Middle East & Africa Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. Middle East & Africa Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Share by Country (2021–2032)

Figure 45. Israel Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. Saudi Arabia Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. UAE Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. Suzhou Shengda Pharmaceuticals Revenue Growth Rate in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

Figure 49. Dongya Pharmaceuticals Revenue Growth Rate in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

Figure 50. DSM Sinochem Revenue Growth Rate in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

Figure 51. Harbin Pharmaceutical Group Revenue Growth Rate in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

Figure 52. Shijiazhuang Pharmaceuticals Revenue Growth Rate in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

Figure 53. Fukang Pharmaceuticals Revenue Growth Rate in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

Figure 54. Job-Health Revenue Growth Rate in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

Figure 55. United Pharmaceuticals Revenue Growth Rate in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

Figure 56. Sandoz Revenue Growth Rate in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

Figure 57. Aurobindo Pharma Revenue Growth Rate in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

Figure 58. Strides Pharma Revenue Growth Rate in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

Figure 59. North China Pharmaceutical Group Revenue Growth Rate in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

Figure 60. Novozymes Revenue Growth Rate in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

Figure 61. Evonik Revenue Growth Rate in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

Figure 62. Teva Revenue Growth Rate in Enzymatic Synthesis of Active Pharmaceutical Ingredients (APIs) Business (2021–2026)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License